Transforming ACL Reconstruction Surgery
With the QuadVantage Autograft System (Instruments and Procedures) your local orthopedic surgeon can provide a superior Quadriceps ACL Reconstruction experience – one that is less traumatic, less likely to fail and easier to recover from.
Amount Raised To Date: $200,000
Minimum Investment: $500 | Price per Share $2.50 | Non-Voting Preferred Shares
ACL Reconstruction - A Growing Market
As society at all ages moves to a more active lifestyle, the incidence of ACL injuries continues to grow – It is no longer an issue just for athletes. According to data from Transparency Market Research 2021, over 900,000 ACL reconstruction surgeries are expected to be performed in North America and Europe in 2023. Worldwide the number of ACL surgeries is approaching 2 Million per year.
Issues with Current
Mainstream ACL reconstruction techniques utilize Patellar, Hamstring or Allograft (cadaver) tendon grafts as replacements for the injured tendon. Key issues continue to plague patient’s that undergo these surgeries;
Postoperative Pain, Swelling & Infection
use of narcotics
To Treat Pain
LONG TERM ISSUES
Knee Pain, Graft Failure
The QuadVantage Quadriceps Autograft System
Based on research conducted over several decades, it is believed that the Quadriceps tendon is superior to Patellar, Hamstring and Allograft alternatives.
The complexity of harvesting the Quadriceps tendon, however, has kept it out of the mainstream.
The Patented QuadVantage Quadriceps Autograft solution makes harvesting of the Quadriceps tendon easier; adding precision, eliminating guesswork and minimizing trauma to the knee – making the procedure locally accessible for ordinary patients at any age.
Eliminates Guesswork Minimizes Trauma & Pain
A BETTER GRAFT
Lower Cost per Case Vs Competition
INVEST IN THE FUTURE
A Comprehensive Solution With Significant Advantages
QuadVantage will provide a full solution to measure, shape, harvest, extract and attach a high performance Quadriceps tendon graft tailored the individual patients needs at any age.
Terms of Offering
QuadVantage Technology, Inc.
Description of Business
Advanced Medical Devices for ACL Reconstruction
Type of Shares
Series CF Non-Voting Preferred Stock , 5% Annual Dividend
Purchase Price of Security Offered
$2.50 per share
Minimum Investment Amount (per investor)
Maximum Target Amount
TARGET OFFERING AMOUNT
Establishes point at which the company can initiate the first close.
Deadline to Reach Target Offering Amount
April 23, 2023
In making an investment decision, Investors must rely on their own examination of the Company and the terms of the Offering, including the merits and risks involved. The Company has filed a Form C with the Securities and Exchange Commission in conjunction with its Offering that provides significant details on the Company, the Securities offered, and the risks involved in making an investment.
INVEST IN THE FUTURE
Why Invest in QuadVantage?
Join The Discussion
Commentary that is abusive, hateful, or fraudulent will be removed.
Frequently Asked Questions
QuadVantage will provide a full solution to measure, shape, harvest, extract and attach a high performance Quadriceps tendon graft tailored the individual patient’s needs at any age.